

HFpEF


Heart Failure with Preserved Ejection Fraction

Bernard Gojer, MD, MPA, FACC

Disclosures: None

EJECTION FRACTION

- Developed by Physiologists in 1950's as a measure of contractility under CONSTANT loading conditions
- NORMAL = 55% to 70%
- LVEF changes with:
 - Preload
 - Afterload
 - Volume
 - Contractility





NORMAL HEART PHYSIOLOGY

- Ventricular contraction involves a "Twisting" and "Untwisting" action
- Mitral Annulus moves up and down
- Creates a SUCTION effect which facilitates Rapid LV Filling in early diastole.
- The "TREPPE" or STAIRCASE effect: As Heart Rate Increases there is a stair step Increase in Contractility.

NET EFFECT

- As HR goes up:
- Contractility Goes Up
- SUCTION increases
- Early Diastolic Filling is accelerated
- LV and Pulmonary Wedge pressures stay LOW





ASYMPTOMATIC DIASTOLIC DYSFUNCTION

> ECHO measures of "Diastolic Dysfunction" alone does not define HFpEF

One study of 2042 patients > 45 years old demonstrated that 28% of asymptomatic patients had ECHO derived evidence of Diastolic Dysfunction. This is considered Stage "B" by ACC/ AHA Guidelines.

(Redfield MM, et al. Burden of systolic and Diastolic Ventricular Dysfunction in the Community. JAMA. 2003: 289: 194)

The presence and severity of "Diastolic Dysfunction" by ECHO increases with Age and may be a precursor to development of Heart Failure

		GESTIVE HEART FAILU or 1 Major and 2 Mi	
	Major	Minor	
HPI -	PND or orthopnea	DOE	
	Rales	Nocturnal cough	
	HJR	Tachycardia	
PE -	\$3	Ankle edema	
	JVD (or elevated CVP)	Hepatomegaly	
Imaging -	CXR pulmonary edema	CXR engorged pulm vessels	
	Cardiomegaly	Pleural effusion	
Empiric!	10lb weight loss with diuretics	Decreased vital capacity	
	(Yancy, et al	I. 2013 ACCF/AHA Heart Failure Guidelin	ne)

CATEGORIES OF HEART FAILURE

HFrEF: Heart Failure with Reduced Ejection Fraction: LVEF < 40%

HFpEF: Heart Failure with Reduced Ejection Fraction: LVEF > 50% (Yancy, et al. 2013 ACCF/AHA Heart Failure Guideline)

HFmrEF: Heart Failure with Mid Range Ejection Fraction: LVEF 41-49% (Ponikowski P, et al. 2016 ESC Guidelines. European Heart Journal, Vol 37, Issue 27, 14 July, 2016. P 2129-2200)

=0


"HFrEF" (Heart Failure with Reduced Ejection Fraction)

CHARACTERISTICS

- Dilated Left Ventricle
- Eccentric Hypertrophy
- LVEF < 40%
- Pulmonary Edema


PROVEN TREATMENTS

- Beta Blockers
- Ace Inhibitors / ARB
- Neprilysin Inhibitors
- Aldosterone Inhibitors
- Digoxin
- AICD / Biventricular Pacing



STRUCTURAL CHANGES IN HFPEF


- Chamber Remodeling
 - Increased Relative Wall thickness & LV Mass
 - Normal End Diastolic Ventricular Volume
 - Increased Left Atrial Volume
- Cardio Myocyte Remodeling
 - Increased myocyte Hypertrophy (Myocytes thicker and shorter)
 - $\,\circ\,$ Matrix Inflammation and fibrosis
 - Increased Collagen Deposition
 - Increased metalloproteinases



FUNCTIONAL CHANGES IN HFPEF





- Decreased Early LV Filling and shift to Late Diastolic Filling
- $\,\circ\,$ Increased dependence on Left Atrial Contraction
- $\,\circ\,$ Increased LV Stiffness and reduced LV Distention
- Increased Diastolic Pressure in Left Ventricle; Left Atrium and Pulmonary Veins
- ALL CHANGES EXACERBATED BY:
- > EXERCISE
- ➤ TACHYCARDIA
- > AFIB (Loss of Atrial Kick)




DYSPNEA ON EXERTION MOST COMMON SYMPTOM IN HEPEF


Pulmonary Capillary Wedge Pressure increases dramatically Decreased Diastolic Filling time In patients with HFpEF during Exercise Decreased Early Left Ventricular Filling 35 Increased Left Ventricular Stiffness 30 Increased Left Ventricular; Left Atrial and Peak exercise 🗌 25 pulmonary vein pressures PCWP, mmHg Right Heart Cath: 20 Diastolic dysfunction PCWP > 15 at rest 15 PCWP > 25 with Exercise 10 Rest 5 Rest Kitzman DW, Higginbotham MB, Cobb FR, et al, 0 J. Am. Coll. Cardiol. 1991; 17; 1065 60 100 120 160 80 140 -0 (As referenced in "Up to Date") LVEDV, mL








		Clinical Variable	Values	Points
	ы	Heavy	Body mass index > 30 kg/m ²	2
	H ₂	Hypertensive	2 or more antihypertensive medicines	1
	F	Atrial Fibrillation	Paroxysmal or Persistent	3
	Ρ	Pulmonary Hypertension	Doppler Echocardiographic estimated Pulmonary Artery Systolic Pressure > 35 mmHg	1
	Е	Elder	Age > 60 years	1
	F	Filling Pressure	Doppler Echocardiographic E/e' > 9	1
	H ₂ FPEF score		Sum (0-9)	
	Total P Probab		2 3 4 5 6 7 3 0.4 0.5 0.6 0.7 0.8 0.9 0.95	89
Borlaug, Reddy, et al				





MUST EXCLUDE THESE DIAGNOSES

CARDIOMYOPATHIES WITH PRESERVED LVEF

- Restrictive Cardiomyopathy
 - Amyloid
 - Hemochromatosis
- Hypertrophic Cardiomyopathy

VALVULAR HEART DISEASE

- Mitral Stenosis or Regurgitation
- Aortic Stenosis or Regurgitation

RIGHT HEART FAILURE

- Primary Pulmonary Hypertension
- Right Ventricular Infarction
- Arrhythmogenic Right Ventricular Cardiomyopathy


PERICARDIAL DISEASE → Constrictive Pericarditis

OBSTRUCTIVE LESIONS


- Atrial Myxoma
- Pulmonary Vein Stenosis


HIGH OUTPUT FAILURE


TRANSIENT LV SYSTOLIC DYSFUNCTION




ΞÓ









ALDOSTERONE INHIBITORS The "TOPCAT" TRIAL


> 3445 patients with HFpEF followed for 3.3 years (Spironolactone vs Placebo)

- Mild reduction in event rate (18.6% vs 20.4%)
- > SUBGROUP ANALYSIS:
 - Patients with BNP > 100pg/ml or NT Pro BNP > 360 pg/ml
 - Combined Endpoint Reduced (15.9% vs 23.6%)
 - Hospitalizations Reduced (11.2% vs 16.9%)
 - Mortality Reduced (8.2% vs 12%)

ACC / AHA Heart Failure Guidelines:

Recommend Aldosterone or Eplerenone for patients with HFpEF AND elevated BNP Who have adequate Renal Function with close follow up of Potassium.

(PITT B, Pfeffer MA, et al. Spironolactone for Heart Failure With Preserved Ejection Fraction. N Engl J Med 2014; 370: 1383)



THINGS THAT DON'T HELP


- BETA BLOCKERS (No Mortality Benefit)
 Use as needed for HTN; or CAD
- ACE INHIBITORS (No Mortality Benefit)
 Use for HTN if renal function good
- ANGIOTENSIN RECEPTOR BLOCKERS


 "CHARM" and "PRESERVE" Trials: No Benefit
- SILDENAFIL (PDE-5 Inhibitors) (For Pulmonary HTN)
 "RELAX" Trial showed No Benefit

- DIGOXIN
 No Benefit
- NITRATES
 No Benefit
- ARNI
 (Angiotensin Receptor Neprilysin Inhibitors)
 NVESTIGATIONAL

=0

(Yancy, et al. 2013 ACCF/AHA Heart Failure Guideline)





Characteristics of Transthyretin Amyloid Cardiomyopathy

➢OLD AGE: M > 65 F > 70

► ECHO (Looks Like HFpEF)

- LVH. Wall thickness > 14 mm
- Normal LV volume and LVEF > 50%
- Thickening of Valves and Atrial Septum
- Dilated Atria

►ECG

- Low Voltage QRS (Despite LVH on ECHO)
- AV Block and Conduction Disease

➢ POLY NEUROPATHY

- o Bilateral Carpal Tunnel Syndrome
- Autonomic Neuropathy (Orthostatic Hypotension)

^{99m}Technetium-Pyrophosphate Imaging Transthyretin Cardiac Amyloidosis

- Measure Activity in Region of Interest of HEART
- Measure Activity in Region of Interest of LUNG
- RATIO of HEART to LUNG > 1.5 Diagnostic for TTR Amyloid

Falk RH, et al. How to Image Cardiac Amyloidosis Circ Cardiovasc Imaging 2014; 7:552-62.



THE END

Thank You for Your Attention